About: Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.23 (+1.36%)
ARTL NASDAQ Artelo Biosciences Inc
Artelo Biosciences Inc share price
Atividade de preço de ARTL
Último preço
$ 2,230
Variação (24h)
0,03 USD (1,36%)
Volume
2.45K
Volume (média 4 sem.)
-
Fechamento anterior
$ 2,20
Último negócio
12 Nov, 1:31 pm GMT+0
Atrasado
12 Nov, 1:31 pm GMT+0
ARTL price performance
Atrasado
12 Nov, 1:31 pm GMT+0
ARTL details
quote.marketSignals